MedTrace Logo

Assessment of Adherence, Quality of Life, Clinical Response and Safety of Daily and Long-Acting Growth Hormone Therapy

NCT04938466 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 19

Last updated 2024-11-19

No results posted yet for this study

Summary

The purpose of the study is to compare quality of life, adherence, insulin resistance, body composition and efficacy of long-acting growth hormone (LAGH) to daily growth hormone (DGH) in children with growth hormone deficiency (GHD). These objectives will be evaluated every 6 months for subjects prior to switch from DGH to LAGH, and 6 months after.

Conditions

  • Growth Hormone Deficiency
  • Growth Hormone Treatment

Interventions

DRUG

Long-Acting Growth Hormone (LAGH)

Long-acting growth hormone (LAGH) treatment

Sponsors & Collaborators

Principal Investigators

  • Bradley S Miller, MD, PhD · University of Minnesota Department of Pediatric Endocrinology

Eligibility

Min Age
2 Years
Max Age
13 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-05
Primary Completion
2024-10-30
Completion
2024-10-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04938466 on ClinicalTrials.gov